Senolytic Drugs Show Promise Against Bone Loss Caused by Chemotherapy

Chemotherapy saves lives, but it often exacts a hidden toll on the skeleton. Patients treated with cytotoxic drugs frequently experience rapid bone deterioration, a condition known as secondary osteoporosis, which raises the risk of fractures, increases morbidity, and diminishes quality of life among cancer survivors. Now a new study in GeroScience suggests that a surprising culprit may be driving much of this damage: cellular senescence, the state in which stressed cells stop dividing but refuse to die, spewing inflammatory molecules into their surroundings. The research also offers an early indication that senolytic drugs, agents designed to selectively eliminate these dysfunctional cells, could help protect the skeleton during cancer treatment.

The study, led by researchers at the University of Texas Health Science Center at San Antonio in collaboration with the Buck Institute for Research on Aging, focused on doxorubicin, one of the most widely used chemotherapeutics and a mainstay of breast cancer therapy. Doxorubicin is known to disrupt bone homeostasis by suppressing osteoblast activity, the work of the cells that build new bone, while simultaneously enhancing osteoclast-mediated resorption, the process by which old bone is broken down. To test whether senescent cells contribute to this deterioration, the team treated young and aged male and female mice with doxorubicin, with the senolytic combination of dasatinib and quercetin, or with both together, and then examined their bones at the molecular, cellular, and structural levels.

The experimental design was thorough. Young mice aged three months and aged mice aged twenty months received weekly intraperitoneal injections of doxorubicin at five milligrams per kilogram for four weeks, while the senolytic pair was administered monthly by oral gavage at doses of five milligrams per kilogram for dasatinib and fifty milligrams per kilogram for quercetin, a regimen chosen because senescent cell turnover is estimated at roughly four weeks. The researchers then harvested femurs, tibiae, humeri, and vertebrae for analysis by high-resolution microcomputed tomography, histology, quantitative gene expression profiling, and deep proteomic mass spectrometry of cortical bone.

The results painted a striking picture of chemotherapy as an accelerant of skeletal aging. Doxorubicin treatment produced hallmark features of accelerated bone aging, including trabecular bone loss, increased marrow adiposity, and upregulation of senescence-associated and inflammatory gene expression. These effects were both sex- and age-dependent, with female mice showing more pronounced deterioration than males. In aged female mice, doxorubicin significantly increased expression of Mmp9, an inflammatory matrix-remodeling gene, in monocytes, while in young male mice it significantly suppressed Alpl, a key osteogenic marker, in osteocytes, indicating that chemotherapy both ignites inflammatory signaling and dampens bone-forming programs.

Senolytic treatment partially reversed these transcriptional changes. In aged female osteocytes, dasatinib and quercetin upregulated the osteogenic genes Alpl and Runx2, while Dmp1 expression increased relative to doxorubicin-treated animals. In young males, the senolytic combination reversed the chemotherapy-associated suppression of osteogenic signaling, with Alpl and Dmp1 expression significantly elevated compared with doxorubicin alone. The authors interpret these findings as evidence that senescent cells contribute to impaired osteoblast function and that clearing them can re-establish at least part of the bone-forming transcriptional program, preserving the function of the bone marrow niche from which both osteoblasts and adipocytes arise.

Perhaps the most technically ambitious component of the study was its proteomic analysis of cortical bone, performed using data-independent acquisition mass spectrometry against a custom spectral library of more than 71,000 peptide entries. In young females, doxorubicin altered 26 bone proteins, and senolytic treatment significantly reversed 14 of them while normalizing 12 others. Structural collagens critical to bone matrix integrity, including Collagen 1A1, Collagen 5A1, and Collagen 11 isoforms, were downregulated by chemotherapy and restored by senolytics, while the proteoglycans Asporin and Osteomodulin, involved in collagen organization and mineralization, were similarly rescued. Conversely, Collagen 6A1 and 6A2, which were elevated by chemotherapy-induced senescence, returned to baseline after senolytic treatment, consistent with reduced inflammatory matrix remodeling.

The proteomics also revealed a metabolic dimension to chemotherapy-induced senescence. Doxorubicin shifted the bone proteome toward glycolysis, elevating glycolytic enzymes such as alpha-enolase, pyruvate kinase, and phosphoglycerate kinase 1, a pattern characteristic of senescent cells, along with stress-associated proteins including HSP70 and cyclophilin A. Senolytic treatment downregulated these enzymes and stress proteins, suggesting that clearing senescent cells normalizes both the extracellular matrix composition and the metabolic state of bone tissue. Notably, the proteins altered by doxorubicin in young animals overlapped substantially with those changed during natural aging, dominated by extracellular matrix and structural proteins as well as SASP-associated factors such as complement C3, cathepsin Z, Gas6, and periostin, reinforcing the idea that chemotherapy drives an aging-like program in the skeleton.

At the structural level, however, the story was more nuanced. MicroCT imaging confirmed that doxorubicin markedly deteriorated trabecular bone, particularly in young females, where bone volume fraction fell from 5.43 percent in controls to 2.52 percent in treated animals. In young males, both senolytics alone and the combination therapy significantly preserved trabecular architecture compared with doxorubicin alone. Yet in females receiving concurrent chemotherapy and senolytics, structural protection was only partial, and in aged animals of both sexes the improvements did not reach statistical significance, likely reflecting greater biological variability and a ceiling effect imposed by already severely reduced baseline bone mass. The authors suggest that molecular remodeling precedes detectable skeletal recovery, and that longer treatment durations and follow-up periods may be needed for molecular gains to translate into architectural restoration.

One of the most compelling findings concerned bone marrow adiposity, the infiltration of fat cells into the marrow cavity, which reflects a shift of mesenchymal stem cells away from bone formation and toward fat production. Doxorubicin significantly expanded marrow adipocyte size and number in both sexes, with the greatest increases in aged females. Senolytic treatment significantly attenuated this expansion in females, reducing adipocyte surface area and number compared with chemotherapy alone, but it did not provide similar protection in males. Because the bone marrow niche also supports hematopoietic stem cell maintenance and immune cell production, preserving this environment may have implications that extend beyond the skeleton to broader hematopoietic and immune function.

The study arrives amid an active scientific debate. Prior work has shown that targeted clearance of senescent cells can alleviate radiation-induced bone loss, and that blocking the p38 MAPK-MK2 pathway can reverse therapy-induced bone deterioration in mice. Other recent research, however, has found that chemotherapy drives rapid bone loss primarily through early suppression of osteoblast activity, even without sustained senescence markers. The new findings support a two-phase model in which early osteoblast suppression drives the initial phase of bone loss while senescent cell accumulation and SASP-mediated signaling contribute at later stages. This framework implies that effective clinical strategies may ultimately need to combine senolytics with osteoanabolic therapies that stimulate bone formation directly, rather than relying on senescence clearance alone.

For patients, the appeal of senolytics lies in what they might offer beyond current options. Standard treatments for chemotherapy-induced bone loss, including bisphosphonates, estrogen therapy, and the RANKL inhibitor denosumab, carry significant limitations: estrogen is contraindicated in hormone-sensitive cancers, bisphosphonates have been linked to osteonecrosis of the jaw and atypical femoral fractures, and denosumab discontinuation can trigger rebound vertebral fractures. Senolytics, by contrast, act by eliminating senescent cells and restoring tissue homeostasis rather than simply blocking resorption, potentially promoting a more anabolic skeletal environment. With approximately 70 percent of people over 65 expected to develop neoplasms by 2040, and with accumulating evidence that chemotherapy-induced senescence affects multiple organ systems including the brain and cardiovascular system, the possibility that a single senescence-targeting intervention could protect bone while benefiting other tissues makes this line of research one to watch closely, even as the authors themselves caution that optimizing treatment timing, dosing, and combination strategies remains essential before clinical translation.

Subject of Research: Senolytic targeting of cellular senescence to mitigate chemotherapy-induced bone loss in mice

Article Title: Targeting cellular senescence mitigates chemotherapy-induced bone loss in young and aged mice

Article References: Izquierdo, D. J., Blancarte-Hernandez, E., Schurman, C. A., Schilling, B., Woloszyk, A., Aguilar, L., Salmon, A., & Glatt, V. (2026). Targeting cellular senescence mitigates chemotherapy-induced bone loss in young and aged mice. GeroScience. https://doi.org/10.1007/s11357-026-02485-4

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02485-4

Keywords: cellular senescence, senolytics, chemotherapy-induced bone loss, doxorubicin, dasatinib, quercetin, osteoporosis, bone marrow adiposity, bone proteomics, SASP, osteoblasts, GeroScience